Compare Equinor ASA (EQNR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs GSK plc — how do they compare? Equinor ASA trades at $43.34 (market cap $101.62B), while GSK plc trades at $46.61 (market cap $91.88B). The key difference: Equinor ASA and GSK plc are close in size by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and GSK plc for 93 Days on average.
| EQNR | GSK | |
|---|---|---|
Market Cap | $101.62B | $91.88B |
Volume | 4,991,782 | 7,730,529 |
Sector | Energy | Health |
52-Week High | $45.75 | $61.18 |
52-Week Low | $22.41 | $43.24 |
Typical Hold Time | 59 Days | 93 Days |
Enterprise Value | $110.31B | $111.88B |
Dividend Yield | 3.63% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $43.415, up 4.34% with strong technical momentum and bullish moving average signals. The stock shows attractive valuation metrics with P/E of 11.63 and EV/EBITDA of 2.39, while maintaining solid profitability with 21.32% ROE. Recent earnings beat expectations in two of the last three quarters, and the company continues shareholder returns through dividends and buybacks.
EQNR presents compelling value with significant upside to the $87.50 consensus price target, though investors face risks from volatile energy prices and declining profit margins. The company's LNG expansion strategy and strong cash flow generation support long-term growth potential, while technical indicators suggest near-term bullish momentum may continue.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
